Navigation Links
Results of NeuroThera Effectiveness and Safety Trial - 2 (NEST-2) Presented at International Stroke Conference 2009
Date:2/20/2009

Encouraging Safety and Efficacy Results Support Follow-on NEST-3 Trial

CARLSBAD, Calif., Feb. 20 /PRNewswire/ -- In a clinical trial sponsored by PhotoThera, Inc., transcranial laser therapy (TLT) for acute ischemic stroke within 24 hours of stroke onset demonstrated improved outcomes for patients, but did not meet statistical significance for efficacy. A post-hoc analysis in patients who had moderate to moderately severe strokes revealed a statistically significant treatment effect. These encouraging results support a follow-on phase III trial, NEST-3.

The results of the NEST-2 study (NeuroThera(R) Effectiveness and Safety Trial - 2) were presented at the American Heart Association's International Stroke Conference in San Diego, CA by Justin Zivin, M.D., Ph.D., Professor of Neurosciences at the University of California San Diego and Principal Investigator for the NEST-2 study. The results were also published online today in Stroke: Journal of the American Heart Association.

NEST-2 was a double-blind, sham-controlled (placebo) trial which enrolled 660 patients. Patients were eligible for inclusion in the study if they were 40-90 years of age, had moderate to severe strokes, and had not received tissue plasminogen activator (tPA). Initiation of treatment had to occur within 24 hours after stroke onset.

In NEST-2, TLT achieved a favorable outcome in 36.3% of patients compared to only 30.9% of patients in the sham group (p-value 0.094). The primary efficacy endpoint was a favorable 90-day score of 0-2 using the modified Rankin Scale (mRS). Mortality rates and serious adverse events (SAEs) did not differ between groups, providing further evidence of the safety of TLT.

A post-hoc analysis of 434 patients who suffered moderate to moderately severe strokes showed a favorable outcome in 51.6% of patients in the TLT group compared to 41.9% of patients in the sham group. This 9.7% treatment effect was statistically significant (p-value 0.044).

"TLT is one of the most promising new therapies that we've seen in a long time, especially as it may expand the treatment window for ischemic stroke to 24 hours. We look forward to commencing NEST-3 to further investigate TLT," stated Professor Werner Hacke, M.D., Ph.D., Chairman of Neurology at the University of Heidelberg, who will join Professor Zivin as Co-Chairman of the NEST-3 Steering Committee.

About Acute Ischemic Stroke

According to the American Stroke Association, stroke is the third leading cause of death in the United States. Ischemic stroke, which accounts for about 83 percent of all strokes, occurs as a result of an obstruction within a blood vessel supplying blood to the brain.

About PhotoThera

PhotoThera, Inc. (www.photothera.com), located in Carlsbad, CA, is developing transcranial laser therapy (TLT) for the treatment of acute ischemic stroke and other neurological diseases and disorders. The company was founded by Jackson Streeter, M.D., a former U.S. Navy flight surgeon and TOPGUN instructor.


'/>"/>
SOURCE PhotoThera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
Breaking Medicine News(10 mins):